Anakinra Versus Placebo for the Treatment of Acute MyocarditIS

  • STATUS
    Recruiting
  • End date
    May 30, 2022
  • participants needed
    120
  • sponsor
    Assistance Publique - Hôpitaux de Paris
Send
Updated on 27 January 2021
See if I qualify

Summary

There is no specific treatment of acute myocarditis, especially during the inflammatory period. Interleukin (IL) is specifically involved during this period and play a role in myocardial oedema. ANAKINRA, an IL-1 Blocker, is a new treatment that has never been evaluated in myocarditis. The benefit for the patient could be important with a reduction of heart failure and ventricular arrhythmias.

Hypothesis : ANAKINRA in addition to standard therapy for treatment of Acute Myocarditis is superior to standard therapy based on an association of beta-blockers and Angiotensin-Converting-Enzyme inhibitor (ACE).

Description

It is a Double Blind Randomized clinical trial Phase IIb of superiority, enrolling two groups: one group treated with the standard of care, defined as the maximum tolerated dosage of any beta blockers and ACE, and placebo versus ANAKINRA in addition to the standard of care in patients treated for an acute Myocarditis.

Patients will be randomized to receive ANAKINRA 100 mg/daily or placebo subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months. Randomization 1:1 will be conducted centrally using the electronic Case Report Form (eCRF).

As an exploratory analysis, a second randomization for ACE discontinuation in patients without left ventricular dysfunction (LVEF > 50%) at one month post discharge will be performed.

One group will stopped the treatment at one month and the second group will continued the ACE for 6 months. This second randomization is in open label.

Details
Condition Acute Myocarditis
Treatment Placebo, ANAKINRA 100 mg/daily subcutaneously
Clinical Study IdentifierNCT03018834
SponsorAssistance Publique - Hôpitaux de Paris
Last Modified on27 January 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 64 yrs?
Gender: Male or Female
Do you have Acute Myocarditis?
Do you have any of these conditions: Do you have Acute Myocarditis??
Do you have any of these conditions: Do you have Acute Myocarditis??
Do you have any of these conditions: Do you have Acute Myocarditis??
Patients hospitalized for Acute myocarditis defined as
Chest Pain (or modification of the ECG) AND Troponin Rise (1.5 Normal range) AND Myocarditis proven by MRI in the first 72h after admission
Age > 18 and <65 years old
Accepting effective contraception during treatment duration (men and women childbearing potential)
Signed informed consent Normal Coronary angiography or coronary CT Scan (made during the previous year is acceptable) (normal is defined as stenosis < 50%) (In the case of patients under 40 with typical MRI of myocarditis, coronary angiography is not mandatory and left to the doctor's discretion)

Exclusion Criteria

Active coronary disease
Clinical Suspicion or proven underlying disease: systemic lupus, antiphospholipid antibodies, Lyme disease, trypanosomiase disease, myositis, signs of sarcoidosis, giant cell myocarditis, treated chronic inflammatory disease, tuberculosis, HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV), Hepatitis B virus (HBV) infection
Latex allergy
Pregnancy, breastfeeding
Contra-indication to ANAKINRA (known hypersensitivity to the active substance or to any of the excipients, neutropenia < 1,5.10^9/L)
Renal failure, Creatine Clearance (CrCl) < 30 ml/min (MDRD)
Malignancy or any comorbidity limiting survival or conditions predicting inability to complete the study
History of malignancy
Non Steroidian Anti Inflammatory drug within the past 14 days
Anti Tumor Necrosis Factor (TNF) within the past 14 days
No affiliation to the French Health Care System "scurit sociale
Hepatic impairment = Child-Pugh Class C
Mechanical ventilation
Circulatory assistance
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note